secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0000950170-22-007826
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Q1 revenue $29M (+55% YoY), net loss ($9.0M), raises FY guidance to $128-133M
--------------------------------------------------------------------------------

- Revenue of $29.0M, up 55% from $18.7M in Q1 2021; driven by increased Lapiplasty kit sales and higher ASPs.
- Net loss attributable to common stockholders was ($9.0M), or ($0.16) per share, vs. ($2.6M) or ($0.07) in Q1 2021.
- Gross margin 81.0% (down from 82.2%); operating expenses rose to $31.6M from $16.8M on higher S&M and G&A investments.
- New five-year $150M loan arrangement ($120M term loan + $30M revolver); $54M drawn to repay existing $30M debt.
- FY 2022 revenue guidance raised to $128M-$133M (prior $125M-$130M); representing ~36%-41% YoY growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017022007826/0000950170-22-007826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017022007826/tmci-20220505.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-007826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer